PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

NCT05520814 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma
PD-1 Inhibitors
Chemoradiotherapy

Interventions

DRUG: PD-1 inhibitors
RADIATION: chemoradiotherapy

Sponsor

Sichuan Cancer Hospital and Research Institute